Global Cancer Vaccines Market 2015-2019

がんワクチンの世界市場:予防ワクチン、治療ワクチン

◆タイトル:Global Cancer Vaccines Market 2015-2019
◆商品コード:IRTNTR6198
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年6月17日
◆ページ数:65
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、がんワクチンの世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、がんワクチンの世界市場規模及び予測、がん予防ワクチン、がん治療ワクチン市場分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Cancer Vaccines
Cancer vaccines are biological preparations that stimulate or strengthen a person’s immune system against cancer. Cancer vaccines are usually administered intravenously. They can be used in both adults and children. The vaccines can be broadly classified into two: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer.
Technavio’s analysts forecast the global cancer vaccines market to grow at a CAGR of 27.24% over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the global cancer vaccines market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various therapeutic and prophylactic cancer vaccines.

This report covers the present scenario and the growth prospects of the global cancer vaccines market for the period 2015-2019 in the following three regions:
• Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil
• EMEA: The principal countries focused upon in this region are the UK; Germany; Italy; France; Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE
• APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India. APAC is one of the major markets that is untapped by the leading vendors

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

Technavio’s report, Global Cancer Vaccines Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global cancer vaccines market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Dendreon
• GlaxoSmithKline
• Merck

[Other Prominent Vendors]
• Aduro BioTech
• Advantagene
• Advaxis
• Agenus
• AlphaVax
• Altor BioScience
• Amgen
• Antigen Express
• Argos Therapeutics
• AVAX Technologies
• Bavarian Nordic
• Biothera
• Bristol-Myers Squibb
• Celldex Therapeutics
• Cel-Sci
• CureVac
• Cytos
• Galena Biopharma
• Genexine
• GlobeImmune
• Gradalis
• Heat Biologics
• Immatics
• ImmunoCellular Therapeutics
• Immutep
• Inovio Pharmaceuticals
• Isa Pharmaceuticals
• Juvaris Biotherapeutics
• MedImmune
• NewLink Genetics
• Northwest Biotherapeutics
• NovaRx
• OncoThyreon
• Oncovir
• Oxford BioMedica
• Prima BioMed
• Progenics
• Provectus Biopharmaceuticals
• Sanofi
• Sotio
• Transgene
• Ubivac
• Vaccinogen
• Vaxon Biotech
• Vical

[Market Driver]
• Increased Prevalence of Cancers
• For a full, detailed list, view our report

[Market Challenge]
• Cold Chain Management
• For a full, detailed list, view our report

[Market Trend]
• Strategic Alliances
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Vaccine Approval Process

07.Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis

08.Market Segmentation by Clinical Application of Vaccines
08.1 Prophylactic Vaccines
08.2 Therapeutic Vaccines

09.Global Prophylactic Vaccines Market
09.1.1 Market Overview
09.1.2 Market Size and Forecast

10.Global Therapeutic Vaccines Market
10.1.1 Market Overview
10.1.2 Market Size and Forecast

11.Geographical Segmentation

12.Buying Criteria

13.Key Brand Analysis
13.1 Comparative Study between Gardasil and Cervarix

14.Pipeline Portfolio
14.1.1 Prostvac
14.1.2 Neuvax
14.1.3 Rindopepimut
14.1.4 MVax
14.1.5 DCVax-L
14.1.6 ProstAtak
14.1.7 Talimogene Laherparepvec
14.1.8 IMA901
14.1.9 Imprime PGG
14.1.10 OncoVAX
14.1.11 Lucanix
14.1.12 DCVAC/PCa

15.Market Growth Drivers

16.Drivers and their Impact

17.Market Challenges

18.Impact of Drivers and Challenges

19.Market Trends

20.Trends and their Impact

21.Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 Merck
21.2.2 Dendreon
21.2.3 GlaxoSmithKline
21.3 Other and Future Prominent Vendors

22.Opportunities for Cancer Vaccine Vendors

23.Key Vendor Analysis
23.1 Dendreon
23.1.1 Key Facts
23.1.2 Business Overview
23.1.3 Recent Developments
23.1.4 SWOT Analysis
23.2 GlaxoSmithKline
23.2.1 Key facts
23.2.2 Business overview
23.2.3 Business segmentation by revenue 2014
23.2.4 Business segmentation by revenue 2013 and 2014
23.2.5 Geographical segmentation by revenue 2014
23.2.6 Business strategy
23.2.7 Recent developments
23.2.8 SWOT analysis
23.3 Merck & Co. Inc.
23.3.1 Key Facts
23.3.2 Business Overview
23.3.3 Business Segmentation by Revenue 2013
23.3.4 Business Segmentation by Revenue 2012 and 2013
23.3.5 Sales by Geography
23.3.6 Business Strategy
23.3.7 Key Developments
23.3.8 SWOT Analysis

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Vaccine Approval Process
Exhibit 3: Global Cancer Vaccines Market 2014-2019 ($ millions)
Exhibit 4: Segmentation of Global Cancer Vaccines Market by Clinical Application of Vaccines
Exhibit 5: Segmentation of Global Cancer Vaccines Market by Clinical Application of Vaccines, 2014
Exhibit 6: Global Prophylactic Vaccines Market 2014-2019 ($ millions)
Exhibit 7: Global Therapeutic Vaccines Market 2014-2019 ($ millions)
Exhibit 8: Segmentation of the Global Cancer Vaccines Market by Geography, 2014
Exhibit 9: Global Cancer Vaccines Market: Comparison of the Major Brands
Exhibit 10: Gardasil and Cervarix: A Comparative Study
Exhibit 11: Key Late-stage Vaccines Under Development
Exhibit 12: Drivers of the Global Cancer Vaccines Market
Exhibit 13: Challenges of the Global Cancer Vaccines Market
Exhibit 14: Trends of the Global Cancer Vaccines Market
Exhibit 15: Global Revenue and YoY Growth Rate of Gardasil 2010-2014
Exhibit 16: Global Revenue and YoY Growth Rate of Provenge 2011-2014
Exhibit 17: Global Revenue and YoY Growth Rate of Cervarix 2010-2014
Exhibit 18: Opportunity Analysis: Global Cancer Vaccine Market
Exhibit 19: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 20: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 21: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 22: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 23: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 24: Merck & Co. Inc.: Sales by Geography 2013



【掲載企業】

Dendreon, GlaxoSmithKline, Merck, Aduro BioTech, Advantagene, Advaxis, Agenus, AlphaVax, Altor BioScience, Amgen, Antigen Express, Argos Therapeutics, AVAX Technologies, Bavarian Nordic, Biothera, Bristol-Myers Squibb, Celldex Therapeutics, Cel-Sci, CureVac, Cytos, Galena Biopharma, Genexine, GlobeImmune, Gradalis, Heat Biologics, Immatics, ImmunoCellular Therapeutics, Immutep, Inovio Pharmaceuticals, Isa Pharmaceuticals, Juvaris Biotherapeutics, MedImmune, NewLink Genetics, Northwest Biotherapeutics, NovaRx, OncoThyreon, Oncovir, Oxford BioMedica, Prima BioMed, Progenics, Provectus Biopharmaceuticals, Sanofi, Sotio, Transgene, Ubivac, Vaccinogen, Vaxon Biotech, Vical

【資料のキーワード】

がんワクチン、がん予防ワクチン、がん治療ワクチン、製薬、医薬品、パイプライン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[がんワクチンの世界市場:予防ワクチン、治療ワクチン] (Global Cancer Vaccines Market 2015-2019 / IRTNTR6198)販売に関する免責事項
[がんワクチンの世界市場:予防ワクチン、治療ワクチン] (Global Cancer Vaccines Market 2015-2019 / IRTNTR6198)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆